Literature DB >> 9066890

Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae.

B Rouse1, C Azen, R Koch, R Matalon, W Hanley, F de la Cruz, F Trefz, E Friedman, H Shifrin.   

Abstract

Maternal phenylketonuria (PKU) in untreated women has resulted in offspring with microcephaly, mental retardation, congenital heart disease (CHD), and intrauterine growth retardation. The Maternal Phenylketonuria Collaborative Study (MPKUCS) was designed to determine the effect of dietary control of blood phenylalanine (Phe) during pregnancy in preventing damage to the fetus associated with untreated Maternal PKU. A cohort of offspring from MPKUS pregnancies was ascertained and examined to evaluate malformations, including CHD, craniofacial abnormalities, microcephaly, intrauterine and postnatal growth retardation, other major and minor defects, and early abnormal neurological signs. For analysis, the women were grouped according to their mean Phe levels in mumol/liter, < or = 360, 361-600, 601-900, or > 900, during critical gestational weeks of 0-8 (N = 203) and 8-12 (N = 190), and average for Phe exposure throughout pregnancy (N = 183). Frequencies of congenital abnormalities increased with increasing maternal Phe levels. Significant relationships included average Phe 0-8 weeks and CHD (P = 0.001); average Phe 8-12 weeks and brain, fetal, and postnatal growth retardation (P < 0.0005 for all), wide nasal bridge (P < 0.0005), and anteverted nares (P = 0.001); and average Phe exposure during the entire pregnancy and neurological signs (P < 0.0005). Although 14% of infants had CHD, none of the CHD occurred at 120-360 mumol/liter and only one (3%) at 361-600 mumol/liter. At levels of 120-360 mumol/liter, there were three infants (6%) with microcephaly, two (4%) with postnatal growth, and none with intrauterine growth retardation, in contrast to 85%, 51%, and 26%, respectively, with Phe above 900 mumol/liter. These data support the concept that women with PKU should begin a low-phenylalanine diet to achieve Phe levels of < 360 mumol/liter prior to conception and should maintain this throughout pregnancy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066890     DOI: 10.1002/(sici)1096-8628(19970303)69:1<89::aid-ajmg17>3.0.co;2-k

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

1.  Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation.

Authors:  Raphaël Teissier; Emmanuel Nowak; Murielle Assoun; Karine Mention; Aline Cano; Alain Fouilhoux; François Feillet; Hélène Ogier; Emmanuel Oger; Loïc de Parscau
Journal:  J Inherit Metab Dis       Date:  2012-06-05       Impact factor: 4.982

Review 2.  Fetal echocardiography: a window to the developing heart.

Authors:  M Regina L Lantin
Journal:  Indian J Pediatr       Date:  2002-06       Impact factor: 1.967

Review 3.  Getting to the heart of the matter: epidemiology of cyanotic heart defects.

Authors:  Jennifer L Kornosky; Hamisu M Salihu
Journal:  Pediatr Cardiol       Date:  2008-01-10       Impact factor: 1.655

Review 4.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

5.  Nasomaxillary hypoplasia and severe orofacial clefting in a child of a mother with phenylketonuria.

Authors:  E Sweeney; A Fryer
Journal:  J Inherit Metab Dis       Date:  2002-02       Impact factor: 4.982

6.  Maternal Phenylketonuria Collaborative Study (MPKUCS)--the 'outliers'.

Authors:  W B Hanley; C Azen; R Koch; K Michals-Matalon; R Matalon; B Rouse; F Trefz; S Waisbren; F de la Cruz
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

7.  Maternal phenylketonuria in Turkey: outcomes of 71 pregnancies and issues in management.

Authors:  Yılmaz Yıldız; Hatice Serap Sivri
Journal:  Eur J Pediatr       Date:  2019-05-03       Impact factor: 3.183

8.  Maternal hyperphenylalaninemia: rapid achievement of metabolic control predicts overall control throughout pregnancy.

Authors:  Teresa Martino; Celide Koerner; Gayane Yenokyan; Julie Hoover-Fong; Ada Hamosh
Journal:  Mol Genet Metab       Date:  2013-02-19       Impact factor: 4.797

9.  Maternal phenylketonuria: the French survey.

Authors:  François Feillet; Véronique Abadie; Jacques Berthelot; Nicole Maurin; Hélène Ogier; Michel Vidailhet; Jean-Pierre Farriaux; Loic de Parscau
Journal:  Eur J Pediatr       Date:  2004-07-06       Impact factor: 3.183

Review 10.  A guide to the recognition of skeletal disorders in the fetus.

Authors:  Rita L Teele
Journal:  Pediatr Radiol       Date:  2006-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.